Estrogens, estrogen receptors and melanoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 5, 2011, Pages 739-747

  De Giorgi, Vincenzo ^a   Gori, Alessia ^a   Grazzini, Marta ^a   Rossari, Susanna ^a   Scarfì, Federica ^a   Corciova, Suzanna ^a   Verdelli, Alice ^a   Lotti, Torello ^a   Massi, Daniela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

estrogen; estrogen receptor b; melanoma; risk; skin

Indexed keywords

2 METHOXYESTRADIOL; ANTIESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; ORAL CONTRACEPTIVE AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION REGULATION; HORMONAL CARCINOGENESIS; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MELANOCYTIC NEVUS; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPARA; NONHUMAN; PHOTOAGING; POSTMENOPAUSE; PREGNANCY OUTCOME; PREMENOPAUSE; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRANSACTIVATION;

EID: 79955836946     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.42     Document Type: Review

References (112)

1. Thornton MJ. The biological actions of estrogens on skin. Exp. Dermatol. 11, 487-502 (2002).
2. Verdier-Sevrain S, Bonte F, Gilchrest B. Biology of estrogensin skin: implications for skin aging. Exp. Dermatol. 15, 83-94 (2006).
3. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. Am. J. Clin. Dermatol. 4, 371-378 (2003).
4. Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen, menopause, and hormone replacement therapy on the skin. J. Am. Acad. Dermatol. 53(4), 555-566 (2005).
5. Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. Clin. Interv. Aging 2(3), 283-297 (2007).
6. Sator PG, Schmidt JB, Sator MO, Huber JC, Honingsmann H. The influence of hormone replacement therapy on skin aging: a pilot study. Maturitas 39, 43-55 (2001).
7. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm. Metab. Res. 39(2), 85-95 (2007).
8. Dao H Jr, Kazin RA. Gender differences in skin: a review of the literature. Gend. Med. 4(4), 308-328 (2007).
9. Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J. Mammary Gland Biol. Neoplasia 3(1), 49-61 (1998).
10. Di Leo A, Messa C, Cavallini A, Linsalata M. Estrogens and colorectal cancer. Curr. Drug. Targets Immune Endocr. Metab. Disord. 1, 1-12 (2001).
11. Pujol P, Rey JM, Nirde P et al. Differential expression of estrogen receptor-a and -p messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res. 58, 5367-5373 (1998).
12. Beatson C. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2, 104-107 (1896).
13. Jensen E, Jacobson HI. Fate of steroidal estrogens in target tissues. In: Biological Activities of Steroids in Relation to Cancer. Pincus G, Vollmer EP (Eds.). Academic Press, NY, USA, 161-174 (1960).
14. Jensen E, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm. Res. 18, 387-414 (1962).
15. Walter P, Green S, Greene G et al. Cloning of the human estrogen receptor cDNA. Proc. Natl Acad. Sci. USA 82, 7889-7893 (1985).
16. Green S, Walter P, Kumar V et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320, 134-139 (1986).
17. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of the human estrogen receptor complementary DNA. Science 231, 1150-1154 (1986).
18. Green S, Walter P, Greene G et al. Cloning of the human estrogen receptor cDNA. J. SteroidBiochem. 24, 77-83 (1986).
19. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 93, 5925-5930 (1996).
20. Tremblay GB, Tremblay A, Copeland NG et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptorp. Mol. Endocrinol. 11, 353-365 (1997).
21. Mosselman S, Polman J, Dijkema R. ERp: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392,49-53 (1996).
22. Ponglikitmongkol M, Green S, Chambon P. Genomic organization of the human oestrogen receptor gene. EMBO J. 7, 3385-3388 (1988).
23. Enmark E, Pelto-Huikko M, Grandien K et al. Human estrogen receptor b-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 82, 4258-4265 (1997).
24. Benecke A, Chambon P, Gronemeyer H. Synergy between estrogen receptor a activation functions AF-1 and AF-2 mediated by transcription intermediary factors TIF2. EMBO Rep. 1(2), 151-157 (2000).
25. Wissink S, van der Burg B, Katzenellenbogen BS, van der Saag PT. Synergistic activation of the serotonin-1A receptor by nuclear factor-kB and estrogen. Mol. Endocrinol. 15, 543-552 (2001).
26. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen signaling via estrogen receptor b. J. Biol. Chem. 285(51), 39575-39579 (2010).
27. Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor b protein in proliferative preinvasive mammary tumors. Cancer Res. 61(6), 2537-2541 (2001).
28. Gustafsson JA, Warner M. Estrogen receptor b in the breast: role in estrogen responsiveness and development of breast cancer. J. Steroid Biochem. Mol. Biol. 74(5), 245-248 (2000).
29. Thomas CG, Ström A, Lindberg K, Gustafsson JA. Estrogen receptor b decreases survival of p53-defective cancer cells after DNA damage by impairing G(2)/M checkpoint signaling. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010- 1011-z (2010) (Epub ahead of print).
30. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A, Gustafsson JA. Tumor repressive functions of estrogen receptor b in SW480 colon cancer cells. Cancer Res. 69(15), 6100-6106 (2009).
31. Lindberg K, Ström A, Lock JG, Gustafsson JA, Haldosén LA, Helguero LA. Expression of estrogen receptor beta increases integrin a1 and integrin b1 levels and enhances adhesion of breast cancer cells. J. Cell Physiol. 222(1), 156-167 (2010).
32. Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor b in human tissues. J. Mol. Endocrinol. 24, 145-155 (2000).
33. Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB. Tissue distribution of estrogen receptor a (ER-a) and b (ER-b) mRNA in the midgestational human fetus. J. Clin. Endocrinol. Metab. 82, 3509-3512 (1997).
34. Thornton MJ, Taylor AH, Mulligan K et al. Oestrogen receptor b is the predominant oestrogen receptor in human scalp skin. Exp. Dermatol. 12, 181-190 (2003).
35. Pelletier G, Ren L. Localization of sex steroid receptors in human skin. Histol. Histopathol. 19, 629-636 (2004).
36. Taylor AH, Guzail M, Al-Azzawi F. Differential expression of oestrogen receptor isoforms and androgen receptor in the normal vulva and vagina compared with vulval lichen sclerosus and chronic vaginitis. Br. J. Dermatol. 158, 319-328 (2008).
37. Kariya Y, Moriya T, Suzuki T et al. Sex steroid hormone receptors in human skin appendage and its neoplasms. Endocr. J. 52, 317-325 (2005).
38. Moverare S, Lindberg MK, Faegermann J et al. Estrogen receptor a, but not estrogen receptor b, is involved in the regulation of the hair follicle cycling as well as the thickness of epidermis in male mice. J. Invest. Dermatol. 124, 22-27 (2002).
39. Chang KC, Wang Y, Oh IG et al. Estrogen receptor b is a novel therapeutic target for photoaging. Mol. Pharmacol. 77, 744-750 (2010).
40. Ghersetich I, Troiano M, De Giorgi V, Lotti T. Receptors in skin ageing and antiageing agents. Dermatol. Clin. 25(4), 655-662, xi (2007).
41. El Safoury O, Rashid L, Ibrahim M. A study of androgen and estrogen receptors a, b in skin tags. Indian J. Dermatol. 55(1), 20-24 (2010).
42. Strouse JJ, Fears TR, Tucker MA et al. Pediatric melanoma: risk factor and survival analysis of the Surveillance, Epidemiology, and End Results database. J. Clin. Oncol. 23, 4735-4741 (2005).
43. Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am. J. Surg. 175(6), 437-444 (1998).
44. Scoggins CR, Ross MI, Reintgen DS et al.; for the Sunbelt Melanoma Trial. Gender-related differences in outcome for melanoma patients. Ann. Surg. 243, 693-698 (2006).
45. Joosse A, de Vries E, Eckel R et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J. Invest. Dermatol. 131(3), 719-726 (2011).
46. Miller JG, Mac Neil S. Gender and cutaneous melanoma. Br. J. Dermatol. 136(5), 657-665 (1997).
47. Miller JG, Gee J, Price A, Garbe C, Wagner M, Mac Neil S. Investigation of oestrogen receptors, sex steroids and soluble adhesion molecules in the progression of malignant melanoma. Mel. Res. 7, 197-208 (1997).
48. Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive infuences and risk of melanoma in women. Intern. J. Epidemiol. 27, 751-757 (1998).
49. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Does the use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy. Mel. Res. 19(5), 327-332 (2009).
50. Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br. J. Cancer 36, 804-809 (1977).
51. Ramcharan S, Pellegrin FA, Ray R et al. The Walnut Creek Contraceptive Drug Study (Volume III). Center for Population Research, National Institute of Health, Bethesda, MD, USA (1981).
52. Feskanich D, Hunter DJ, Willett WC et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br. J. Cancer 81, 918-923 (1999).
53. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population based case-control study. Ann. Oncol. 20, 358-364 (2009).
54. Adam SA, Sheaves SA, Wright NH et al. A case-control study of the possible association between oral contraceptives and malignantmelanoma. Br. J. Cancer 44, 45-50 (1981).
55. Bain C, Hennekens Ch, Speizer FE et al. Oral contraceptive use and malignant melanoma. J. Natl Cancer Inst. 68, 537-539 (1982).
56. Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J. Natl Cancer Inst. 70, 827-831 (1983).
57. Beral V, Evans S, Shaw H et al. Oral contraceptive use and malignant melanoma in Australia. Br. J. Cancer 50, 681-685 (1984).
58. Holman CDJ, Armstrong BK, Heenan PJ. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br. J. Cancer 50, 673-680 (1984).
59. Helmrich SP, Rosenberg L, Kaufman DW et al. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. J. Natl. Cancer Inst. 72, 617-620 (1984).
60. Gallagher R P, Elwood JM, Hill GB et al. Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. Br. J. Cancer 52, 901-907 (1985).
61. Green A, Bain C. Hormonal factors and melanoma in women. Med. J. Aust. 142, 446-448 (1985).
62. Osterlind A, Tucker MA, Stone BJ et al. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int. J. Cancer 42, 821-824 (1988).
63. Zanetti R, Franceschi S, Rosso S et al. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int. J. Epidemiol. 19, 522-526 (1990).
64. Hannaford PC, Villard-Mackintosh L, Vessey MP et al. Oral contraceptives and malignant melanoma. Br. J. Cancer 63, 430-433 (1991).
65. Lê MG, Cabanes PA, Desvignes V et al. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 3, 199-205 (1992).
66. Palmer JR, Rosenberg L, Strom BL et al. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 3, 547-554 (1992).
67. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am. J. Epidemiol. 141, 943-950 (1995).
68. Westerdahl J, Olsson H, Masback A et al. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br. J. Cancer 73, 1126-1131 (1996).
69. Lea CS, Holly EA, Hartge P et al. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am. J. Epidemiol. 165, 505-513 (2007).
70. Naldi L, Altieri A, Imberti GL et al. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case- control study from Italy. Ann. Epidemiol. 15, 545-550 (2005).
71. Osterlind A. Hormonal and reproductive factors in melanoma risk. Clin. Dermatol. 10(1), 75-78 (1992).
72. Gupta A, Driscoll MS. Do hormones infuence melanoma? Facts and controversies. Clin. Dermatol. 28(3), 287-292 (2010).
73. Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control 19(5), 437-442 (2008).
74. Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br. J. Dermatol. 38, 122-124 (1998).
75. Pfahlberg A, Hassan K, Wille L et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev. 25, 309-315 (1997).
76. Karagas MR, Stuckel TA, Dykes J et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br. J. Cancer 86, 1085-1092 (2002).
77. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol. Biomarkers Prev. 3, 661-668 (1994).
78. MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br. J. Cancer 90, 770-772 (2004).
79. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int. J. Cancer 67, 327-332 (1996).
80. Lens MB, Rosdahl I, Ahlbom A et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J. Clin. Oncol. 22(21), 4369-4375 (2004).
81. Pack GT, Scharnagel IM. The prognosis for malignant melanoma in the pregnant woman. Cancer 4, 324-334 (1951).
82. Riberti C, Marola G, Bertani A. Malignant melanoma: the adverse effect of pregnancy. Br. J. Plastic Surg. 34, 338-339 (1981).
83. Miller E, Barnea Y, Gur E et al. Malignant melanoma and pregnancy: second thoughts. J. Plast. Reconstr. Aesthet. Surg. 20, 1-6 (2009).
84. Kaae J, Andersen A, Boyd HA, Wohlfahrt J, Melbye M. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am. J. Epidemiol. 165(11), 1265-1270 (2007).
85. Lambe M, Thorn M, Sparen P et al. Malignant melanoma: reduced risk associated with early childbearing and multiparity. Mel. Res. 6, 147-153 (1996).
86. Karagas MR, Zens MS, Stukel TA et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control 17(1), 11-19 (2006).
87. Driscoll MS, Grant-Kels JM. Nevi and melanoma in the pregnant woman. Clin. Dermatol. 28(3), 287-292 (2010).
88. Brinton LA, Moghissi KS, Westhoff CL, Lamb EJ, Scoccia B. Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil. Steril. 94(5), 1787-1792 (2010).
89. Ishida H, Wada K, Masuda T et al. Critical role of estrogen receptor on anoikis and invasion of squamous cell carcinoma. Cancer Sci. 98, 636-643 (2007).
90. Dobos J, Timar J, Bocsi J et al. In vitro and in vivo antitumor effect of 2- methoxyestradiol on human melanoma. Int. J. Cancer 112, 771-776 (2004).
91. Dobos J. [Endocrine factors infuencing melanoma progression]. Magy Onkol. 53(1), 47-50 (2009).
92. Richardson B, Price A, Wagner M et al. Investigation of female survival beneft in metastatic melanoma. Brit. J. Dermatol. 80(12), 2025-2033 (1999).
93. Mueck AO, Seeger H. Breast cancer: are oestrogen metabolites carcinogenic? Maturitas 57(1), 42-46 (2007).
94. Mao A, Paharkova-Vatchkova V, Hardy J, Miller MM, Kovats S. Estrogen selectively promotes the differentiation of dendritic cells with characteristics of Langerhans cells. J. Immunol. 175(8), 5146-5151 (2005).
95. Krahn-Bertil E, Dos Santos M, Damour O, Andre V, Bolzinger MA. Expression of estrogen-related receptor b (ERRb) in human skin. Eur. J. Dermatol. 20(6), 719-723 (2010).
96. Mor G, Sapi E, Abrahams VM et al. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J. Immunol. 170(1), 114-122 (2003).
97. Widyarini S, Domanski D, Painter N, Reeve VE. Estrogen receptor signaling protects against immune suppression by UV radiation exposure. Proc. Natl Acad. Sci. USA 103, 12837-12842 (2006).
98. Cho J, Allanson M, Reeve VE. Oestrogen receptor-p signalling protects against transplanted skin tumor growth in the mouse. Photochem. Photobiol. Sci. 9, 608-614 (2010).
99. De Giorgi V, Mavilia C, Massi D et al. Estrogen receptor expression in cutaneous melanoma. Arch. Dermatol. 145(1), 30-33 (2009).
100. Schmidt AN, Nanney LB, Boyd AS et al. Oestrogen receptor-p expression in melanocytic lesions. Exp. Dermatol. 15, 971-980 (2006).
101. Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor p in normal skin, melanocytic nevi and malignant melanoma. J. Dermatol. 35, 215-221 (2008).
102. Matsuoka H, Tsubaki M, Yamazoe Y et al. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/ PI3K/Akt pathways. Exp. Cell Res. 315(12), 2022-2032 (2009).
103. Dewhurst LO, Gee JW, Rennie IG, MacNeil S. Tamoxifen, 17p-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br. J. Cancer-75(6), 860-68 (1997).
104. Cocconi G, Bella M, Calabresi F et al. Treatment of metastatic malignant melanoma with decarbazine plus tamoxifen. N. Engl. J. Med. 327, 516-523 (1992).
105. Rusthoven JJ, Quirt IC, Iscoe NA et al. Randomized, double-blind, placebo controlled trial comparing the response rates of carmustine, dacarbazine, and cispladn with and without tamoxifen in patients with metastatic melanoma. J. Clin. Oncol. 14, 2083-2090 (1996).
106. Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A Phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer 85, 1979-1984 (1999).
107. Falkson CI, Ibrahim J, Kirkwood JN, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group Study J. Clin. Oncol. 16, 1743-1751 (1998).
108. Creagan ET, Suman VJ, Dalton RJ et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J. Clin. Oncol. 17, 1884-1890 (1999).
109. Lens MB, Reiman T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Cancer 98, 1355-1361 (2003).
110. De Giorgi V, Gori A, Grazzini M et al. The initiation and progression of melanoma: estrogens or estrogen receptors? Mel. Res. 20(1), 64-65 (2010).
111. De Giorgi V, Mavilia C, Massi D et al. The role of estrogens in melanoma and skin cancer. Carcinogenesis 30(4), 720 (2009).
112. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERfP) expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 11(3), 537-551 (2004).